Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”

Li-Xuan Sang

Li-Xuan Sang, Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China

Abstract Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8: 1361-1384. We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.

Key Words: Correction; Probiotic mixture VSL#3; Intestinal barrier function; Chronic diseases; Cytokines; Therapeutic use

CORRECTION

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3:An overview of basic and clinical studies in chronic diseases.World J Clin Cases2020; 8:1361-1384 PMID: 32368530 DOI: 10.12998/wjcc.v8.i8.1361.

We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital,China Medical University. We published an article about probiotic mixture VSL#3 on April 26, 2020. Now we solemnly declare that the studies mentioned in this article[1]evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.